Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pharmacokinetics, Safety, and Tolerability of SHP465 Mixed Amphetamine Salts After Administration of Multiple Daily Doses in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder

Autor: Alan R Kugler, Katarina Ilic, Nora McNamara, Brian Yan

Publikováno v: CNS Drugs

Background Given the limited treatment options for younger children with attention-deficit/hyperactivity disorder (ADHD), a clinical study for SHP465 treatment was warranted. Objectives We aimed to evaluate the pharmacokinetics, safety, and tolerabil

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16af88fb928f0af3496d04517a05a575
https://pubmed.ncbi.nlm.nih.gov/34826114

Zobrazit plný text záznamu

Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P‐gp Substrate

Autor: Mosun Ayan-Oshodi, Douglas E. James, Jennifer A. Zimmer, Brian A. Willis, Scott A. Monk, Scott W. Andersen, Alan R. Kugler, Jamie Mullen

Publikováno v: The Journal of Clinical Pharmacology. 60:586-594

Lanabecestat, a novel β-site amyloid precursor protein-cleaving enzyme 1 inhibitor evaluated for Alzheimer treatment, inhibits P-glycoprotein (P-gp) activity in vitro. After oral 50-mg lanabecestat administration, gastric fluid lanabecestat concentr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c781a369f1140b257f43abcecb817d64
https://doi.org/10.1002/jcph.1558

Zobrazit plný text záznamu

A Phase 3 open-label study of the efficacy, safety and pharmacokinetics of buccally administered midazolam hydrochloride for the treatment of status epilepticus in pediatric Japanese subjects

Autor: Harumi Yoshinaga, Alan R. Kugler, Shinichi Takeda, Martha Fournier, Arturo Benitez

Publikováno v: Epilepsy research. 174

Background In Japan, intravenous (IV) administration of antiepileptic drugs in a healthcare setting is the preferred treatment option that is both licensed and recommended for initial treatment of status epilepticus (SE). However, prompt conveyance t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d8907a2dcbace555a1ec76194e43514
https://pubmed.ncbi.nlm.nih.gov/34020149

Zobrazit plný text záznamu

BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides

Autor: Kyoko Matsuguma, Susanna Eketjäll, Tatsuya Yoshihara, Fumihiko Azuma, Glen Hughes, Kei Sakamoto, Alan R. Kugler, Robert C. Alexander, Naoki Uchida, Muir Russell, Samantha Budd Haeberlein, Shunji Matsuki

Publikováno v: The Journal of Clinical Pharmacology. 57:1460-1471

Lanabecestat (AZD3293; LY3314814) is an orally active potent inhibitor of human β-secretase 1 in clinical development for the treatment of Alzheimer disease. In this first Japanese clinical study for an Alzheimer disease intervention to include cere

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e7b8ab5558f619a1893ded62f15383ce
https://doi.org/10.1002/jcph.950

Zobrazit plný text záznamu

Simultaneous quantitation of the BACE1 inhibitor AZD3293 and its metabolite AZ13569724 in human matrices by LC–MS/MS

Autor: Yan Li, Mark Hoffmann, Dennis L. Miller, Paul Severin, Alan R. Kugler, Scott A. Monk

Publikováno v: Bioanalysis. 9:813-826

Aim: AZD3293 is a novel BACE1 inhibitor in Phase III development for Alzheimer's disease. Sensitive and robust bioanalytical methods were required to quantitate AZD3293 and its metabolite AZ13569724 in human biological matrices. Methodology/results:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c90b674146000f7c9b513415ba980d15
https://doi.org/10.4155/bio-2017-0003

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics

Autor: Karin Kaspersson, Juliette Janson, Johanna Fälting, Gvido Cebers, Samantha Budd Haeberlein, Fredrik Jeppsson, Susanna Eketjäll, Alan R. Kugler, Anna Bogstedt, Robert C. Alexander

Publikováno v: Journal of Alzheimer's Disease

A growing body of pathological, biomarker, genetic, and mechanistic data suggests that amyloid accumulation, as a result of changes in production, processing, and/or clearance of brain amyloid-β peptide (Aβ) concentrations, plays a key role in the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65beb77a630968cc8f1f9d69367c2ef9
https://doi.org/10.3233/jad-150834

Zobrazit plný text záznamu

Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease

Autor: Andrea Varrone, Per Svenningsson, Katarina Varnäs, Peter Johnström, Anna K. Kirjavainen, Margaret Minkwitz, Zsolt Cselényi, Juha O. Rinne, Nahid Amini, Joel A. Posener, Aurelija Jucaite, Semi Helin, Samantha L. Budd, Alan R. Kugler, Lars Farde, Christer Halldin

Publikováno v: Brain. 138:2687-2700

Impaired mitochondrial function, oxidative stress and formation of excessive levels of reactive oxygen species play a key role in neurodegeneration in Parkinson’s disease. Myeloperoxidase is a reactive oxygen generating enzyme and is expressed by m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12a0536de57e1a2b3f3347b6dc3ccc89
https://doi.org/10.1093/brain/awv184

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání